Biotherapy Treatment on Features of Microcrystalline Polyarthritis

Crystal-Induced Arthritis Clinical Trial

— FUMBLE  

Official title:

Features of Microcrystalline Polyarthritis Treated by Biologics and Evolution - FUMBLE Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04005625
• Other study ID #: 29BRC19.0056
• Status: Completed
• Start date: May 1, 2019
• Est. completion date: June 1, 2020

Study information

• Verified date: September 2020
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study will involve adult patient who had received any biologic agent for microcrystalline disease in western France (Tours, Le Mans, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.

Investigators will answer retrospectively a questionnaire that covers patient and disease data, biologic agent use, efficacy and adverse events.

Description:

This is a retrospective multicentric study of all patients treated by biologic for microcrystalline disease in France in western France (Tours, Le Mans, Nantes, La Roche sur Yon, Orléans, Angers, Rennes, Poitiers et Brest) between 01/01/2010 and 31/12/2018.

The investigators will collect all clinical (diagnosis of gout CCPD or hydroxyapatitis, tender and swollen joint count), biological (blood results: ESR, CRP, uric acid, synovial analysis), radiological data (X-rays performed and their description) .

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: June 1, 2020
• Est. primary completion date: June 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Crystal- induced arthritis

• Treatment by biologic

• In western France

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Arthritis
• Crystal-Induced Arthritis

Locations

Country	Name	City	State
France	CHRU de Brest	Brest

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment duration	Duration of treatment by biologic in days	one year
Secondary	number of synovitis	number of synovitis on 44	inclusion